Get the Stockscreener App
157.14
2.87%
-4.65
Axsome Therapeutics Inc stock is traded at $157.14, with a volume of 873.08K.
It is down -2.87% in the last 24 hours and down -25.87% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$161.79
Open:
$160.43
24h Volume:
873.08K
Relative Volume:
0.91
Market Cap:
$8.23B
Revenue:
$708.24M
Net Income/Loss:
$-188.30M
P/E Ratio:
-42.03
EPS:
-3.7392
Net Cash Flow:
$-70.99M
1W Performance:
-6.66%
1M Performance:
-25.87%
6M Performance:
-14.69%
1Y Performance:
+25.71%
1-Day Range:
$156.09
$160.43
1-Week Range:
$155.18
$170.80
52-Week Range:
$123.50
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
157.14 | 8.23B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-26 | Resumed | Truist | Buy |
| Jul-21-26 | Initiated | BMO Capital Markets | Outperform |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
2 Under-the-Radar Stocks to Buy and Hold - The Motley Fool
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Why Axsome Therapeutics shares are falling today - Quiver Quantitative
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
Axsome Therapeutics, Inc. (19X.F) Stock Price, News, Quote & History - Yahoo Finance
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – DUS:19X - TradingView
Axsome Therapeutics Stock: 12 Straight Red Days, Down 15% - Trefis
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - Yahoo Finance
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Motley Fool
Tangible book value per share of Axsome Therapeutics, Inc. – HAN:19X - TradingView
Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities - The Globe and Mail
Axsome Therapeutics Stock Extends An 11-Day Losing Streak To A 14% Loss - Trefis
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290 - Moomoo
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13% - Trefis
Axsome Therapeutics on Pace for Longest Losing Streak Since December 2018 -- Data Talk - Moomoo
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $295.00 by Analysts at Royal Bank Of Canada - MarketBeat
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days - Trefis
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - The Motley Fool
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
Before markets open Nov. 2, Axsome will report results and host an 8 a.m. call. - Stock Titan
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 - GlobeNewswire
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting - Lelezard
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
AXSOME THERAPEUTICS, INC. : DEUTSCHE BANK CUTS TARGET PRICE TO $267 FROM $280 - webull.com
EBITDA per share of Axsome Therapeutics, Inc. – HAN:19X - tradingview.com
Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat
Axsome Therapeutics slides as investors weigh launch execution and policy risks - Quiver Quantitative
Axsome Therapeutics, Inc. Revenue Breakdown – HAN:19X - tradingview.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Axsome Therapeutics Is Maintained at Buy by Deutsche Bank - Moomoo
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - marketscreener.com
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - Yahoo Finance
Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions - Simply Wall Street
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - Moomoo
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251 - Moomoo
AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - Yahoo Finance
Axsome Therapeutics Announces Results of the Shared Goals - globenewswire.com
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story? - Yahoo Finance
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - Yahoo Finance
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
| Mark Jacobson | Officer |
Sep 03 '26 |
Proposed Sale |
208.35 |
10,000 |
2,083,500 |
0 |
| Herriot Tabuteau | Officer |
Aug 06 '26 |
Proposed Sale |
210.13 |
4,660 |
979,206 |
0 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Sale |
213.95 |
4,660 |
997,007 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
4.95 |
4,660 |
23,067 |
11,889 |
| Herriot Tabuteau | Officer |
Aug 05 '26 |
Proposed Sale |
212.85 |
45,004 |
9,579,101 |
0 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Option Exercise |
4.95 |
45,004 |
222,770 |
52,233 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Sale |
212.01 |
45,004 |
9,541,298 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Sale |
240.25 |
49,666 |
11,932,256 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
4.95 |
49,666 |
245,847 |
56,895 |
3.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):